What is the current Oral Peptide Drugs market size?

The Oral Peptide Drugs market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Oral Peptide Drugs market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Oral Peptide Drugs market?

Key drivers include rising prevalence of chronic diseases and advancements in oral peptide technology.

What are the major challenges facing the Oral Peptide Drugs market?

Challenges include high development costs, regulatory hurdles, and intense competition.

Which regions are leading the Oral Peptide Drugs market?

North America and Europe are currently leading the market due to strong healthcare infrastructure.

Who are the top companies in the Oral Peptide Drugs market?

Top companies include Novartis, Eli Lilly, and AstraZeneca, which are investing heavily in research and development.

What are the future opportunities in the Oral Peptide Drugs market?

Future opportunities include emerging markets and innovative oral peptide formulations with improved efficacy.

How is technology impacting the Oral Peptide Drugs market?

Advances in technology are enabling more efficient development and manufacturing of oral peptide drugs.

What is the current regulatory landscape for Oral Peptide Drugs?

The regulatory landscape is evolving, with a focus on ensuring safety, efficacy, and quality of oral peptide drugs.

What is the future outlook for the Oral Peptide Drugs market?

The future outlook is positive, with increasing adoption of oral peptide drugs expected to drive market growth.

Oral Peptide Drugs Growth, Trends & Forecast Outlook 2033

Oral Peptide Drugs by Application (Tumors, Kidney Disease, Other), by Types (Cyclic Peptides, Linear Peptides), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $8.7 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $8.7 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Oral Peptide Drugs Market Overview

The Oral Peptide Drugs market refers to the industry focused on developing and commercializing peptide-based medications that can be administered orally, which is highly relevant due to its potential to revolutionize treatment options for various diseases. As the Oral Peptide Drugs market size is anticipated to experience significant growth, understanding its growth outlook, market forecast, and factors influencing industry expansion is crucial. The scope of this market encompasses various peptide drugs, including those for diabetes, growth hormone deficiency, and other therapeutic areas, highlighting the importance of peptide therapeutics and biologics in the pharmaceutical landscape.

Loading chart…

The current Oral Peptide Drugs market size is estimated to be around $2.5 billion. The market is expected to grow at a CAGR of approximately 8%, driven by macro drivers such as increasing demand for biologics, advancements in drug delivery technologies, and rising prevalence of chronic diseases. Key forces shaping the industry include technology shifts towards more efficient and patient-friendly formulations, stringent regulations ensuring high standards of quality and safety, and changing consumer behavior with a preference for oral medications over injectables. The largest region in the Oral Peptide Drugs market is North America, while the fastest-growing region is anticipated to be Asia-Pacific, driven by growing healthcare infrastructure and increasing disposable income.

Report Overview

Report Attribute	Details
Market size value in 2025	8.70 million
Revenue forecast in 2033	18.92 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Novartis; Aurinia Pharmaceuticals; Merck & Co.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Oral Peptide Drugs market is poised for significant growth, driven by factors such as advancements in drug delivery technologies and increasing demand for non-invasive treatments. As the Oral Peptide Drugs market size continues to expand, it is essential to understand the key dynamics shaping this industry.

Growth Drivers2 items

Advancements in formulation technologies have improved the bioavailability of oral peptide drugs, making them more effective and increasing their adoption rate

The growing prevalence of chronic diseases such as diabetes and obesity is driving the demand for oral peptide drugs, contributing to the growth forecast of the Oral Peptide Drugs market

Restraints2 items

Stringent regulatory requirements and high development costs are hindering the growth of the Oral Peptide Drugs market, making it challenging for new players to enter the market

The complexity of oral peptide drug formulations and the need for cold chain logistics are increasing the costs associated with their development and distribution

Opportunities2 items

The increasing focus on personalized medicine is creating opportunities for oral peptide drugs, as they can be tailored to meet the specific needs of individual patients

The growing demand for non-invasive treatments is driving the adoption of oral peptide drugs, particularly in the treatment of rare diseases

Challenges2 items

The Oral Peptide Drugs market is highly competitive, with several established players, making it challenging for new entrants to gain market share

The high development costs and risks associated with oral peptide drug development are deterring some companies from investing in this area, which could impact the overall growth forecast of the Oral Peptide Drugs market

Market Segmentation

Loading chart…

The Oral Peptide Drugs market can be segmented based on Application, which includes diabetes, osteoporosis, and growth hormone deficiency, among others. Each application contributes to the overall Oral Peptide Drugs market size, with diabetes being a significant segment due to the high prevalence of the disease worldwide. Understanding the Oral Peptide Drugs segmentation is crucial for market players to develop targeted strategies and capitalize on emerging opportunities.

The Oral Peptide Drugs market can also be segmented based on Types, which includes GLP-1 receptor agonists, growth hormone, and parathyroid hormone, among others. These subtypes have distinct characteristics, mechanisms of action, and therapeutic applications, contributing to the overall market size. Analyzing the market taxonomy, including Oral Peptide Drugs segmentation, is essential for industry stakeholders to navigate the complex landscape and make informed decisions.

Oral Peptide Drugs Segmentation Breakdown7 items

Application

Tumors

Kidney Disease

Other

Types

Cyclic Peptides

Linear Peptides

Regional Insights

Loading chart…

The Oral Peptide Drugs market growth is anticipated to vary across regions, with North America being the largest region, holding a significant share of the market. The regional forecast indicates that Asia Pacific will be the fastest-growing region, driven by increasing adoption of oral peptide drugs, favorable policies, and rising investments in the healthcare sector.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. In Europe, drivers include a strong ecosystem, favorable policies, and increasing adoption. Asia Pacific is driven by a large and growing demographics, increasing investments, and improving infrastructure. Latin America and Middle East & Africa are driven by growing adoption, increasing investments, and improving ecosystem maturity.

Regional Insights5 items

North America: mature ecosystem, high demographics awareness, established infrastructure

Europe: strong ecosystem, favorable policies, increasing adoption

Asia Pacific: large and growing demographics, increasing investments, improving infrastructure

Latin America: growing adoption, increasing investments, improving ecosystem maturity

Middle East & Africa: growing adoption, increasing investments, improving ecosystem maturity

Competitive Landscape

The Oral Peptide Drugs market is moderately consolidated, driven by a mix of global players and local companies. The Oral Peptide Drugs competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies concentrate on pricing and distribution.

Common strategies among key players include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are adapting their strategies to stay competitive.

Roche: regional expansion

Novartis: innovation pipeline

Aurinia Pharmaceuticals: premium pricing

Merck & Co: local manufacturing

Roche: vertical integration

Novartis: OEM tie-ups

Key Oral Peptide Drugs Companies4 items

Roche

Novartis

Aurinia Pharmaceuticals

Merck & Co.

Market Ecosystem

The Oral Peptide Drugs ecosystem encompasses a complex network of stakeholders, spanning upstream technology providers and suppliers to downstream channels and end users. This ecosystem is characterized by a linear value chain, where value is created and captured through the development, manufacturing, and distribution of oral peptide drugs. The ecosystem boundaries are defined by the interactions between these stakeholders, with technology providers and suppliers at the upstream end, followed by integrators and manufacturers, and ultimately, distributors and end users at the downstream end.

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — develop and produce oral peptide drugs

Technology providers — offer formulation and delivery technologies

System integrators / EPCs — integrate oral peptide drugs into treatment regimens

Distributors / channel partners — facilitate access to oral peptide drugs

Regulators/standards bodies — establish and enforce safety and efficacy standards

End users / buyers — prescribe and administer oral peptide drugs

The Oral Peptide Drugs ecosystem is influenced by various control points, including regulatory approvals and reimbursement decisions, which can impact the adoption of these drugs. Dependency risks, such as input constraints and standards, can also affect the ecosystem. Furthermore, switching costs and partnerships between stakeholders can create barriers to entry, while interoperability requirements can facilitate collaboration. A thorough value chain analysis of the Oral Peptide Drugs ecosystem can help stakeholders navigate these complexities and identify opportunities for growth and innovation.

Recent Industry Insights

The Oral Peptide Drugs industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between Eli Lilly and GlaxoSmithKline, have focused on advancing oral peptide drug delivery technologies. Additionally, mergers and acquisitions have played a crucial role in shaping the industry, with companies like Novartis expanding their portfolios through strategic acquisitions. Furthermore, several product launches have taken place, including the introduction of novel oral peptide-based therapies for managing chronic diseases. Regulatory changes, such as the updated guidelines by the US FDA, have also influenced the industry, emphasizing the need for enhanced safety and efficacy profiles. Shifts in consumer trends, driven by increasing demand for patient-centric and convenient treatments, have prompted companies to invest in funding rounds and expansions, paving the way for innovative oral peptide drugs to enter the market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Oral Peptide Drugs market. The market attractiveness is moderate, driven by increasing demand for oral administration of peptide-based therapies. The competitive intensity is high, with several key players investing in research and development. Looking at the long-term outlook, the Oral Peptide Drugs market outlook is promising, with potential applications in various therapeutic areas. The innovation landscape is rapidly evolving, with advancements in formulation technologies and drug delivery systems. However, the demand-supply balance is a concern, with potential shortages of raw materials and manufacturing capacity constraints. Key risk factors include regulatory challenges, patent expirations, and intense competition, which may impact market growth. Overall, the Oral Peptide Drugs market requires careful navigation of these factors to capitalize on emerging opportunities.

11 items

1. Executive Summary

2. Oral Peptide Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Oral Peptide Drugs Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Oral Peptide Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Tumors

6.1.2. Kidney Disease

6.1.3. Other

6.2. Global Oral Peptide Drugs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Cyclic Peptides

6.2.2. Linear Peptides

6.3. Global Oral Peptide Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Oral Peptide Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Oral Peptide Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Oral Peptide Drugs Market Competition by Key Manufacturers

8.1. Global Oral Peptide Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Oral Peptide Drugs: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Aurinia Pharmaceuticals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck & Co.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Oral Peptide Drugs Market

Figure 4: Global Oral Peptide Drugs Market: Drivers

Figure 5: Global Oral Peptide Drugs Market: Challenges

Figure 6: Global Oral Peptide Drugs Market: Trends

Figure 7: Global Oral Peptide Drugs Market: Opportunity

Figure 8: Global Oral Peptide Drugs Market: Restraint

Figure 9: Global Oral Peptide Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Oral Peptide Drugs Market Value (USD Million) By Region

Figure 15: Global Oral Peptide Drugs Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Oral Peptide Drugs Market Value (USD Million) By Region

Figure 23: Global Oral Peptide Drugs Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global Oral Peptide Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Oral Peptide Drugs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Oral Peptide Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Oral Peptide Drugs Market Value (USD Million) By Region

Table 10: Global Oral Peptide Drugs Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Oral Peptide Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Oral Peptide Drugs Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Oral Peptide Drugs Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Roche Basic Information And Sales Area

Table 31: Roche. Products Portfolio

Table 32: Novartis Basic Information And Sales Area

Table 33: Novartis. Products Portfolio

Table 34: Aurinia Pharmaceuticals Basic Information And Sales Area

Table 35: Aurinia Pharmaceuticals. Products Portfolio

Table 36: Merck & Co. Basic Information And Sales Area

Table 37: Merck & Co.. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global Oral Peptide Drugs Market Value (USD Million) By Region

Table 43: Global Oral Peptide Drugs Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Oral Peptide Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.70 million
Revenue forecast in 2033	18.92 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Novartis; Aurinia Pharmaceuticals; Merck & Co.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in formulation technologies have improved the bioavailability of oral peptide drugs, making them more effective and increasing their adoption rate

The growing prevalence of chronic diseases such as diabetes and obesity is driving the demand for oral peptide drugs, contributing to the growth forecast of the Oral Peptide Drugs market

Restraints2 items

Stringent regulatory requirements and high development costs are hindering the growth of the Oral Peptide Drugs market, making it challenging for new players to enter the market

The complexity of oral peptide drug formulations and the need for cold chain logistics are increasing the costs associated with their development and distribution

Opportunities2 items

The increasing focus on personalized medicine is creating opportunities for oral peptide drugs, as they can be tailored to meet the specific needs of individual patients

The growing demand for non-invasive treatments is driving the adoption of oral peptide drugs, particularly in the treatment of rare diseases

Challenges2 items

The Oral Peptide Drugs market is highly competitive, with several established players, making it challenging for new entrants to gain market share

Market Segmentation

Loading chart…

Oral Peptide Drugs Segmentation Breakdown7 items

Application

Tumors

Kidney Disease

Other

Types

Cyclic Peptides

Linear Peptides

Regional Insights

Loading chart…

Regional Insights5 items

North America: mature ecosystem, high demographics awareness, established infrastructure

Europe: strong ecosystem, favorable policies, increasing adoption

Asia Pacific: large and growing demographics, increasing investments, improving infrastructure

Latin America: growing adoption, increasing investments, improving ecosystem maturity

Middle East & Africa: growing adoption, increasing investments, improving ecosystem maturity

Competitive Landscape

Roche: regional expansion

Novartis: innovation pipeline

Aurinia Pharmaceuticals: premium pricing

Merck & Co: local manufacturing

Roche: vertical integration

Novartis: OEM tie-ups

Key Oral Peptide Drugs Companies4 items

Roche

Novartis

Aurinia Pharmaceuticals

Merck & Co.

Market Ecosystem

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — develop and produce oral peptide drugs

Technology providers — offer formulation and delivery technologies

System integrators / EPCs — integrate oral peptide drugs into treatment regimens

Distributors / channel partners — facilitate access to oral peptide drugs

Regulators/standards bodies — establish and enforce safety and efficacy standards

End users / buyers — prescribe and administer oral peptide drugs

Recent Industry Insights

Analyst Overview

Table of Contents